As one of the world's leading biotech companys, GenScript has established a comprehensive drug development platform to integrate antibody engineering and antibody production technologies. Our scientists, with extensive experience in antibody drug development, provide superior services such as antibody humanization and antibody sequencing.
The biopharmaceuticals market in the U.S. is expected to increase to $144 billion by 2016, with an annual growth rate of 11.2%. Monoclonal antibody (mAbs) drugs represent a primary sector of the biopharmaceuticals market. The specificity of mAbs has tremendous clinical value, making them highly effective therapeutic agents. Many large pharmaceutical companies are increasing their investment in mAb research after the success of drugs such as Remicade™ and Rituxan™.
|Antibody Sequencing||Antibody Humanization|
|Custom Antibody Drug Development||Biomolecular Interaction Analysis|
|In Vitro Assay and Screening||In Vivo Efficacy and Safety|
|Chimeric Antibody Generation||Antigen Production|
|Antibody Transient Expression||Premium Hybridoma Development|
|Antibody Stable Cell Line||Antibody Production|